"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...
Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...
4d
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...
The global antidiabetics market is on a strong growth trajectory, with sales projected to soar from USD 106.3 billion in 2024 to USD 298.2 billion by 2034. This substantial increase reflects a robust ...
Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S. Compounding pharmacies ...
(This Mar. 6 story has been corrected to clarify that the judge denied an injunction, not barred copies, in the headline) ...
(Reuters) - A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular ...
The offer may show employers how hard drug manufacturers will compete based on price, in at least some situations.
Novo Nordisk announced a new cash-pay option for its blockbuster weight-loss drug Wegovy, offering a monthly dose at $499 and home delivery. The move follows competitor Eli Lilly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback